Oral Tirzepatide
US$ 24.98
insulin drugs glp 1 receptor agaonist market GLP-1 Agonist Growth Analysis Bahrain Insulin Drugs and Glucagon-Like
Description
More than a decade later, in 2005, exenatide (a synthetic version of exendin-4) was approved as the first anti-diabetes medication in the GLP-1 receptor agonist class by the U.S
Combined anabolic and micronutrient vulnerabilities in these populations may influence musculoskeletal resilience
Lancet 2002;359:82430.PubMed 7
Brock, Kristain
In 2023, the Indian GLP-1 market was valued at USD 105.7 million and is projected to grow at a CAGR of 27.5%, reaching approximately USD 578.9 million by 2030
Semaglutide Though other GLP-1s have been around longer, Novo Nordisks Ozempic is probably the most widely known
